Last reviewed · How we verify

Valchlor 0.016 % Topical Gel

Rochester Skin Lymphoma Medical Group, PLLC · Phase 2 active Small molecule

Valchlor 0.016 % Topical Gel is a Small molecule drug developed by Rochester Skin Lymphoma Medical Group, PLLC. It is currently in Phase 2 development. Also known as: topical nitrogen mustard, mechlorethamine hydrochloride, mechlorethamine gel.

At a glance

Generic nameValchlor 0.016 % Topical Gel
Also known astopical nitrogen mustard, mechlorethamine hydrochloride, mechlorethamine gel
SponsorRochester Skin Lymphoma Medical Group, PLLC
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Valchlor 0.016 % Topical Gel

What is Valchlor 0.016 % Topical Gel?

Valchlor 0.016 % Topical Gel is a Small molecule drug developed by Rochester Skin Lymphoma Medical Group, PLLC.

Who makes Valchlor 0.016 % Topical Gel?

Valchlor 0.016 % Topical Gel is developed by Rochester Skin Lymphoma Medical Group, PLLC (see full Rochester Skin Lymphoma Medical Group, PLLC pipeline at /company/rochester-skin-lymphoma-medical-group-pllc).

Is Valchlor 0.016 % Topical Gel also known as anything else?

Valchlor 0.016 % Topical Gel is also known as topical nitrogen mustard, mechlorethamine hydrochloride, mechlorethamine gel.

What development phase is Valchlor 0.016 % Topical Gel in?

Valchlor 0.016 % Topical Gel is in Phase 2.

Related